{"protocolSection": {"identificationModule": {"nctId": "NCT02443298", "orgStudyIdInfo": {"id": "1311.14"}, "secondaryIdInfos": [{"id": "2014-004932-20", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "AbbVie", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma", "officialTitle": "Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma."}, "statusModule": {"statusVerifiedDate": "2019-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-06-23", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2017-10-13", "type": "ACTUAL"}, "completionDateStruct": {"date": "2018-02-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-05-11", "studyFirstSubmitQcDate": "2015-05-11", "studyFirstPostDateStruct": {"date": "2015-05-13", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2019-02-01", "resultsFirstSubmitQcDate": "2019-03-18", "resultsFirstPostDateStruct": {"date": "2019-04-10", "type": "ACTUAL"}, "dispFirstSubmitDate": "2018-09-12", "dispFirstSubmitQcDate": "2018-09-12", "dispFirstPostDateStruct": {"date": "2018-09-13", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-03-18", "lastUpdatePostDateStruct": {"date": "2019-04-10", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AbbVie", "class": "INDUSTRY"}, "collaborators": [{"name": "Boehringer Ingelheim", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true}, "descriptionModule": {"briefSummary": "The objectives of this trial are primarily to evaluate the efficacy and safety of BI 655066/ABBV-066 (risankizumab) as compared to placebo over a 24-week treatment period in severe asthma patients. The primary endpoint is time to first asthma worsening during the planned 24 week treatment period for active vs. placebo treated patients on top of standard of care therapy. Upon demonstration of a meaningful clinical response, another important objective is the identification of biomarkers that can be used to target patients who will likely respond to treatment with BI 655066/ABBV-066 (risankizumab)."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 214, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Risankizumab", "type": "EXPERIMENTAL", "description": "Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe with 90 milligram/ milliliter (mg/mL) risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20).", "interventionNames": ["Drug: risankizumab"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe consisting of matching placebo to risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20).", "interventionNames": ["Drug: placebo"]}], "interventions": [{"type": "DRUG", "name": "placebo", "description": "Matching placebo for risankizumab", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "risankizumab", "description": "Monoclonal IgG antibody", "armGroupLabels": ["Risankizumab"], "otherNames": ["ABBV-066", "BI 655066"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Time to First Asthma Worsening During the Planned 24 Week Treatment Period", "description": "Time to first asthma worsening during the planned 24 week treatment period:\n\nAsthma worsening was defined as the occurrence of any one of the following four criteria:\n\na) Decrease from baseline of \u226530% in morning peak expiratory flow (PEF) on at least 2 consecutive days. b) Increase from baseline of \u226550% and an increase of least 4 puffs in daily use of rescue medication for at least 2 consecutive days. c) Increase from baseline of \u22650.75 units in ACQ5. d) Severe asthma exacerbations defined as initiation of systemic corticosteroids (prednisone or equivalent) for 3 or more consecutive days for asthma. Additionally, for subjects on maintenance systemic corticosteroids, at least doubling of the maintenance dose resulting in a total daily dose of \u2265 20 mg for three or more consecutive days was considered a severe asthma exacerbation.", "timeFrame": "24 weeks"}], "secondaryOutcomes": [{"measure": "Time to First Asthma Worsening During the Planned 24 Week Treatment Period According to Alternative Definition", "description": "Time to first asthma worsening during the planned 24 week treatment period according to alternative definition:\n\nAsthma worsening was defined as the occurrence of any one of the following four criteria:\n\na) Decrease from baseline of \u226530% in morning peak expiratory flow (PEF) on at least 2 consecutive days. b) Increase from baseline of \u226550% and an increase of least 4 puffs in daily use of rescue medication for at least 2 consecutive days. c) Increase from baseline of \u22650.5 units in ACQ5. d) Severe asthma exacerbations defined as initiation of systemic corticosteroids (prednisone or equivalent) for 3 or more consecutive days for asthma. Additionally, for subjects on maintenance systemic corticosteroids, at least doubling of the maintenance dose resulting in a total daily dose of \u2265 20 mg for three or more consecutive days was considered a severe asthma exacerbation.", "timeFrame": "24 weeks"}, {"measure": "Annualized Rate of Asthma Worsening During the Planned 24 Week Treatment Period", "description": "Annualized rate of asthma worsening during the planned 24 week treatment period.\n\nAsthma worsening was defined as the occurrence of any one of the following four criteria:\n\na) Decrease from baseline of \u226530% in morning peak expiratory flow (PEF) on at least 2 consecutive days. b) Increase from baseline of \u226550% and an increase of least 4 puffs in daily use of rescue medication for at least 2 consecutive days. c) Increase from baseline of \u22650.75 units in ACQ5. d) Severe asthma exacerbations defined as initiation of systemic corticosteroids (prednisone or equivalent) for 3 or more consecutive days for asthma. Additionally, for subjects on maintenance systemic corticosteroids, at least doubling of the maintenance dose resulting in a total daily dose of \u2265 20 mg for three or more consecutive days was considered a severe asthma exacerbation.\n\nMean is Annualized rate.", "timeFrame": "24 weeks"}, {"measure": "Time to First Severe Asthma Exacerbation During the Planned 24 Week Treatment Period", "description": "Time to first severe asthma exacerbation during the planned 24 week treatment period. Severe asthma exacerbation was defined as initiation of systemic corticosteroids (prednisone or equivalent) for 3 or more consecutive days for asthma. Additionally, for subjects on maintenance systemic corticosteroids, at least doubling of the maintenance dose resulting in a total daily dose of \u2265 20 mg for three or more consecutive days was considered a severe asthma exacerbation.", "timeFrame": "24 weeks"}, {"measure": "Annualized Rate of Severe Asthma Exacerbation During the Planned 24-week Treatment Period", "description": "Annualized rate of severe asthma exacerbation during the planned 24-week treatment period.\n\nSevere asthma exacerbation was defined as initiation of systemic corticosteroids (prednisone or equivalent) for 3 or more consecutive days for asthma. Additionally, for subjects on maintenance systemic corticosteroids, at least doubling of the maintenance dose resulting in a total daily dose of \u2265 20 mg for three or more consecutive days was considered a severe asthma exacerbation.\n\nMean is Annualized rate.", "timeFrame": "24 weeks"}, {"measure": "Trough Forced Expiratory Volume in 1 Second (FEV1) In-clinic Change From Baseline at Week 24", "description": "Trough forced expiratory volume in 1 second (FEV1) in-clinic change from baseline at week 24.", "timeFrame": "Baseline and 24 weeks"}, {"measure": "Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) In-clinic Change From Baseline at Week 24", "description": "Post-bronchodilator forced expiratory volume in 1 second (FEV1) in-clinic change from baseline at week 24.", "timeFrame": "Baseline and 24 weeks"}, {"measure": "Weekly Asthma Control Questionaire Score at Week 24", "description": "The score at week 24 is the average of the responses to the five ACQ5 questions for the week preceding the Week 24 visit. The ACQ5 asks patients to rate the severity of their asthma symptoms and the degree to which asthma affected their sleep and other daily activities. The scale for all five ACQ5 questions range from the best possible answer of 0 (No symptoms, None, Never) to the worst possible answer of 6 (very severe, unable to sleep, totally limited). The ACQ5 score can range from 0.0 (best) to 6.0 (worst).", "timeFrame": "24 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n1. Pre-bronchodilator clinic measured forced expiratory volume (FEV1) of =40% and =85% of predicted normal.\n2. One year history of asthma diagnosed by a physician, and have FEV1 reversibility of =12% and an absolute change of at least 200 mL after administration of 400 \u00b5g salbutamol.\n3. Must be on at least medium dose inhaled corticosteroids and at least one other asthma controller medication for at least one year.\n4. Must have documented history of two or more severe asthma exacerbations in the last 12 months.\n\nExclusion criteria:\n\n1. Patients with a significant disease other than asthma.\n2. Patients who are not able to produce sputum or sputum samples of sufficient quality.\n3. Patients who had clinically relevant history of intubation for asthma exacerbation in the past year.\n4. Patients diagnosed with any concurrent respiratory disease.\n5. Recent history (within 6 months) of myocardial infarction or hospitalized for cardiac failure in the past year.\n6. Patients who have undergone thoracotomy with pulmonary resection.\n7. Patients who have undergone bronchial thermoplasty or radiotherapy procedure in the past year or have planned procedures during the study.\n8. Patients taking oral corticosteroids with a total daily dose of more than 20 mg prednisone (or equivalent) in the past 6 weeks.\n9. Pregnant or nursing women.\n10. Women of childbearing potential that, if sexually active, is unwilling to use a highly effective method of birth control.\n11. Clinically relevant acute infections or chronic infections.\n12. Have received any live bacterial or live viral vaccination in the last12 weeks.\n13. Have received Bacille Calmette-Guerin (BCG) vaccination in the last 12 months.\n14. Have received treatment with ustekinumab (Stelara\u00ae).\n15. Have received treatment with any other biologics in the last 3 months or within 6 times the half-life of the compound.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Boehringer Ingelheim", "affiliation": "Boehringer Ingelheim", "role": "STUDY_CHAIR"}], "locations": [{"facility": "WCCT Global, LLC", "city": "Costa Mesa", "state": "California", "zip": "92626", "country": "United States", "geoPoint": {"lat": 33.64113, "lon": -117.91867}}, {"facility": "El Camino Hospital", "city": "Mountain View", "state": "California", "zip": "94040", "country": "United States", "geoPoint": {"lat": 37.38605, "lon": -122.08385}}, {"facility": "IMMUNOe Research Centers", "city": "Centennial", "state": "Colorado", "zip": "80112", "country": "United States", "geoPoint": {"lat": 39.57916, "lon": -104.87692}}, {"facility": "Yale New Haven Hospital", "city": "New Haven", "state": "Connecticut", "zip": "06504", "country": "United States", "geoPoint": {"lat": 41.30815, "lon": -72.92816}}, {"facility": "Clinical Research Trials of Florida, Inc.", "city": "Tampa", "state": "Florida", "zip": "33607", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "Northwestern University", "city": "Chicago", "state": "Illinois", "zip": "60611", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Johns Hopkins Hospital", "city": "Baltimore", "state": "Maryland", "zip": "21224", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Brigham and Women's Hospital", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Washington University School of Medicine", "city": "Saint Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "VA WNY Healthcare System", "city": "Buffalo", "state": "New York", "zip": "14215", "country": "United States", "geoPoint": {"lat": 42.88645, "lon": -78.87837}}, {"facility": "American Health Research, Inc.", "city": "Charlotte", "state": "North Carolina", "zip": "28207", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Coastal Carolina Health Care, P.A.", "city": "New Bern", "state": "North Carolina", "zip": "28562", "country": "United States", "geoPoint": {"lat": 35.10849, "lon": -77.04411}}, {"facility": "Wake Forest School of Medicine", "city": "Winston-Salem", "state": "North Carolina", "zip": "27104", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Temple University School of Medicine", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19140", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "University of Pittsburgh Medical Center", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15213", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Research Protocol Mgmt Spc", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15243", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "MedTrial, LLC", "city": "Columbia", "state": "South Carolina", "zip": "29204", "country": "United States", "geoPoint": {"lat": 34.00071, "lon": -81.03481}}, {"facility": "VitaLink Research", "city": "Greenville", "state": "South Carolina", "zip": "29615", "country": "United States", "geoPoint": {"lat": 34.85262, "lon": -82.39401}}, {"facility": "Respiratory and Sleep Disorders Specialists", "city": "The Woodlands", "state": "Texas", "zip": "77380", "country": "United States", "geoPoint": {"lat": 30.15799, "lon": -95.48938}}, {"facility": "O and O Alpan, LLC", "city": "Fairfax", "state": "Virginia", "zip": "22030", "country": "United States", "geoPoint": {"lat": 38.84622, "lon": -77.30637}}, {"facility": "ULB Hopital Erasme", "city": "Bruxelles", "zip": "1070", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"facility": "Brussels - UNIV St-Luc", "city": "Bruxelles", "zip": "1200", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"facility": "UZ Leuven", "city": "Leuven", "zip": "3000", "country": "Belgium", "geoPoint": {"lat": 50.87959, "lon": 4.70093}}, {"facility": "Centre Hospitalier Universitaire de Li\u00e8ge", "city": "Li\u00e8ge", "zip": "4000", "country": "Belgium", "geoPoint": {"lat": 50.63373, "lon": 5.56749}}, {"facility": "Vancouver General Hospital", "city": "Vancouver", "state": "British Columbia", "zip": "V5Z 1M9", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "Burlington Lung Clinic", "city": "Burlington", "state": "Ontario", "zip": "L7N 3V2", "country": "Canada", "geoPoint": {"lat": 43.38621, "lon": -79.83713}}, {"facility": "Airway Inflammometry Laboratory", "city": "Hamilton", "state": "Ontario", "zip": "L8N 4A6", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"facility": "HOP CHU de Grenoble", "city": "Grenoble", "zip": "38043", "country": "France", "geoPoint": {"lat": 45.16667, "lon": 5.71667}}, {"facility": "HOP Nord", "city": "Marseille", "zip": "13915", "country": "France", "geoPoint": {"lat": 43.29551, "lon": 5.38958}}, {"facility": "HOP Arnaud de Villeneuve", "city": "Montpellier", "zip": "34295", "country": "France", "geoPoint": {"lat": 43.61092, "lon": 3.87723}}, {"facility": "HOP Nord La\u00ebnnec", "city": "Nantes", "zip": "44093", "country": "France", "geoPoint": {"lat": 47.21725, "lon": -1.55336}}, {"facility": "HOP Bichat", "city": "Paris", "zip": "75018", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Praxis Dr. Linnhoff, Berlin", "city": "Berlin", "zip": "10717", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "MECS Research GmbH, Berlin", "city": "Berlin", "zip": "12203", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Berufsgenossenschaftliches Universit\u00e4tsklinikum Bergmannsheil gGmbH", "city": "Bochum", "zip": "44789", "country": "Germany", "geoPoint": {"lat": 51.48165, "lon": 7.21648}}, {"facility": "Praxis Dr. med. Claus Keller", "city": "Frankfurt", "zip": "60389", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "IKF Pneumologie GmbH & Co. KG", "city": "Frankfurt", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Medaimun GmbH", "city": "Frankfurt", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Hamburger Institut f\u00fcr Therapieforschung GmbH (HIT)", "city": "Hamburg", "zip": "20354", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "Praxis Dr. Hoffmann, Hannover", "city": "Hannover", "zip": "30173", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"facility": "Universit\u00e4tsklinikum des Saarlandes", "city": "Homburg/Saar", "zip": "66421", "country": "Germany", "geoPoint": {"lat": 49.32637, "lon": 7.33867}}, {"facility": "Universit\u00e4tsklinikum Schleswig-Holstein, Campus Kiel", "city": "Kiel", "zip": "24105", "country": "Germany", "geoPoint": {"lat": 54.32133, "lon": 10.13489}}, {"facility": "KPPK GmbH, Studienzentrum", "city": "Koblenz", "zip": "56068", "country": "Germany", "geoPoint": {"lat": 50.35357, "lon": 7.57883}}, {"facility": "KLB Gesundheitsforschung L\u00fcbeck GmbH", "city": "L\u00fcbeck", "zip": "23552", "country": "Germany", "geoPoint": {"lat": 53.86893, "lon": 10.68729}}, {"facility": "Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz", "city": "Mainz", "zip": "55131", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "Institut f\u00fcr klinische Forschung GmbH", "city": "Neu-Isenburg", "zip": "63263", "country": "Germany", "geoPoint": {"lat": 50.04832, "lon": 8.69406}}, {"facility": "IFG Institut f\u00fcr Gesundheitsf\u00f6rderung GmbH", "city": "R\u00fcdersdorf", "zip": "15562", "country": "Germany", "geoPoint": {"lat": 51.1, "lon": 11.45}}, {"facility": "Chungbuk National University Hospital", "city": "Cheongju", "zip": "361-771", "country": "Korea, Republic of", "geoPoint": {"lat": 36.63722, "lon": 127.48972}}, {"facility": "Chonnam National University Hospital", "city": "Gwangju", "zip": "501-757", "country": "Korea, Republic of", "geoPoint": {"lat": 35.15472, "lon": 126.91556}}, {"facility": "Korea University Guro Hospital", "city": "Seoul", "zip": "08308", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "The Catholic University of Korea, St.Paul's Hospital", "city": "Seoul", "zip": "130-709", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "HagaZiekenhuis", "city": "Den Haag", "zip": "2545 CH", "country": "Netherlands", "geoPoint": {"lat": 52.07667, "lon": 4.29861}}, {"facility": "Leids Universitair Medisch Centrum (LUMC)", "city": "Leiden", "zip": "2333 ZA", "country": "Netherlands", "geoPoint": {"lat": 52.15833, "lon": 4.49306}}, {"facility": "Gibinski Univ.Clin.Cnter of Silesian Med.Uni.Katowice,Outpat", "city": "Katowice", "zip": "40-752", "country": "Poland", "geoPoint": {"lat": 50.25841, "lon": 19.02754}}, {"facility": "Specjalistyczny Osrodek Alergologiczno-Intern. ALL-MED", "city": "Krakow", "zip": "30033", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Univ. Hospital in Krakow,Pulmonology Clinical Dept", "city": "Krakow", "zip": "31066", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Barlicki University Hospital No. 1", "city": "Lodz", "zip": "90 141", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Barlicki University Hospital No. 1", "city": "Lodz", "zip": "90141", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Chang Gung Memorial Hospital Keelung", "city": "Keelung", "zip": "20401", "country": "Taiwan", "geoPoint": {"lat": 25.12825, "lon": 121.7419}}, {"facility": "China Medical University Hospital", "city": "Taichung", "zip": "40447", "country": "Taiwan", "geoPoint": {"lat": 24.1469, "lon": 120.6839}}, {"facility": "Celerion Inc", "city": "Belfast", "zip": "BT9 6AD", "country": "United Kingdom", "geoPoint": {"lat": 54.59682, "lon": -5.92541}}, {"facility": "Bradford Royal Infirmary", "city": "Bradford", "zip": "BD9 6RJ", "country": "United Kingdom", "geoPoint": {"lat": 53.79391, "lon": -1.75206}}, {"facility": "Glenfield Hospital", "city": "Leicester", "zip": "LE3 9QP", "country": "United Kingdom", "geoPoint": {"lat": 52.6386, "lon": -1.13169}}, {"facility": "The Medicines Evaluation Unit", "city": "Manchester", "zip": "M23 9QZ", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "Wishaw General Hospital", "city": "Wishaw", "zip": "ML2 0DP", "country": "United Kingdom", "geoPoint": {"lat": 55.76667, "lon": -3.91667}}]}, "referencesModule": {"references": [{"pmid": "34706172", "type": "DERIVED", "citation": "Brightling CE, Nair P, Cousins DJ, Louis R, Singh D. Risankizumab in Severe Asthma - A Phase 2a, Placebo-Controlled Trial. N Engl J Med. 2021 Oct 28;385(18):1669-1679. doi: 10.1056/NEJMoa2030880."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "All patients were screened for eligibility to participate in the trial. Patients attended a specialist sites which ensured that they (the patients) met all strictly implemented inclusion/exclusion criteria. Patients were not to be randomized to trial treatment if any one of the specific entry criteria was violated.", "recruitmentDetails": "This was a randomized, double-blind, placebo-controlled, parallel-group multicenter study to assess the efficacy and safety of risankizumab, an IL-23p19 monoclonal antibody, compared to placebo in patients with severe persistent asthma.", "groups": [{"id": "FG000", "title": "Risankizumab", "description": "Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe with 90 milligram/ milliliter (mg/mL) risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20)"}, {"id": "FG001", "title": "Placebo", "description": "Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe consisting of matching placebo to risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20)"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "105"}, {"groupId": "FG001", "numSubjects": "109"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "101"}, {"groupId": "FG001", "numSubjects": "104"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "5"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Randomized Set (RS): This patient set included all randomized patients, whether treated or not.", "groups": [{"id": "BG000", "title": "Risankizumab", "description": "Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe with 90 milligram/ milliliter (mg/mL) risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20)"}, {"id": "BG001", "title": "Placebo", "description": "Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe consisting of matching placebo to risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20)"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "105"}, {"groupId": "BG001", "value": "109"}, {"groupId": "BG002", "value": "214"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "54.1", "spread": "11.3"}, {"groupId": "BG001", "value": "52.3", "spread": "12.5"}, {"groupId": "BG002", "value": "53.2", "spread": "11.9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "69"}, {"groupId": "BG001", "value": "64"}, {"groupId": "BG002", "value": "133"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "36"}, {"groupId": "BG001", "value": "45"}, {"groupId": "BG002", "value": "81"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "6"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "102"}, {"groupId": "BG001", "value": "106"}, {"groupId": "BG002", "value": "208"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "22"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "17"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "84"}, {"groupId": "BG001", "value": "88"}, {"groupId": "BG002", "value": "172"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Oral corticosteroid (OCS) use at baseline", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Yes", "measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "32"}]}, {"title": "No", "measurements": [{"groupId": "BG000", "value": "90"}, {"groupId": "BG001", "value": "92"}, {"groupId": "BG002", "value": "182"}]}]}]}, {"title": "Baseline Morning peak expiratory flow (PEF)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Liter/Minute (L/min)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "299.34", "spread": "110.50"}, {"groupId": "BG001", "value": "309.56", "spread": "115.34"}, {"groupId": "BG002", "value": "304.54", "spread": "112.84"}]}]}]}, {"title": "Baseline 24 Hour Rescue Medication Use", "description": "Baseline 24 Hour Rescue Medication Use: Average over the 14 days prior to randomization", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Puff", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3.17", "spread": "3.81"}, {"groupId": "BG001", "value": "3.89", "spread": "4.78"}, {"groupId": "BG002", "value": "3.53", "spread": "4.34"}]}]}]}, {"title": "Baseline First 5 questions of the Asthma Control Questionnaire (ACQ5) Score", "description": "Baseline ACQ5 is the mean of last 2 available measurements in last 2 weeks prior to Visit 2, that is, 14 days prior to the administration of the first dose. Weekly score is average of responses to the five questions. ACQ5 asks patients to rate the severity of their asthma symptoms and the degree to which asthma affected their sleep and other daily activities. The scale for all five questions range from the best possible answer of 0 (No symptoms, None, Never) to the worst possible answer of 6 (very severe, unable to sleep, totally limited). ACQ5 score can range from 0.0 (best) to 6.0 (worst).", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Unit on scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2.15", "spread": "1.15"}, {"groupId": "BG001", "value": "2.39", "spread": "1.17"}, {"groupId": "BG002", "value": "2.27", "spread": "1.17"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Time to First Asthma Worsening During the Planned 24 Week Treatment Period", "description": "Time to first asthma worsening during the planned 24 week treatment period:\n\nAsthma worsening was defined as the occurrence of any one of the following four criteria:\n\na) Decrease from baseline of \u226530% in morning peak expiratory flow (PEF) on at least 2 consecutive days. b) Increase from baseline of \u226550% and an increase of least 4 puffs in daily use of rescue medication for at least 2 consecutive days. c) Increase from baseline of \u22650.75 units in ACQ5. d) Severe asthma exacerbations defined as initiation of systemic corticosteroids (prednisone or equivalent) for 3 or more consecutive days for asthma. Additionally, for subjects on maintenance systemic corticosteroids, at least doubling of the maintenance dose resulting in a total daily dose of \u2265 20 mg for three or more consecutive days was considered a severe asthma exacerbation.", "populationDescription": "Full Analysis Set (FAS): All randomized patients who received at least one dose of treatment.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "80% Confidence Interval", "unitOfMeasure": "Days", "timeFrame": "24 weeks", "groups": [{"id": "OG000", "title": "Risankizumab", "description": "Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe with 90 milligram/ milliliter (mg/mL) risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20)"}, {"id": "OG001", "title": "Placebo", "description": "Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe consisting of matching placebo to risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "109"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "40.00", "lowerLimit": "30.00", "upperLimit": "52.00"}, {"groupId": "OG001", "value": "85.50", "lowerLimit": "63.00", "upperLimit": "131.00"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "This was analyzed by using a Cox proportional hazards model that included treatment and the stratification factor of OCS use at baseline as fixed effects.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0255", "statisticalMethod": "Cox proportional hazards model", "paramType": "Hazard Ratio (HR)", "paramValue": "1.46", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.18", "ciUpperLimit": "1.81", "estimateComment": "Comparison of Risankizumab to Placebo"}]}, {"type": "SECONDARY", "title": "Time to First Asthma Worsening During the Planned 24 Week Treatment Period According to Alternative Definition", "description": "Time to first asthma worsening during the planned 24 week treatment period according to alternative definition:\n\nAsthma worsening was defined as the occurrence of any one of the following four criteria:\n\na) Decrease from baseline of \u226530% in morning peak expiratory flow (PEF) on at least 2 consecutive days. b) Increase from baseline of \u226550% and an increase of least 4 puffs in daily use of rescue medication for at least 2 consecutive days. c) Increase from baseline of \u22650.5 units in ACQ5. d) Severe asthma exacerbations defined as initiation of systemic corticosteroids (prednisone or equivalent) for 3 or more consecutive days for asthma. Additionally, for subjects on maintenance systemic corticosteroids, at least doubling of the maintenance dose resulting in a total daily dose of \u2265 20 mg for three or more consecutive days was considered a severe asthma exacerbation.", "populationDescription": "Full Analysis Set (FAS): All randomized patients who received at least one dose of treatment.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "80% Confidence Interval", "unitOfMeasure": "Days", "timeFrame": "24 weeks", "groups": [{"id": "OG000", "title": "Risankizumab", "description": "Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe with 90 milligram/ milliliter (mg/mL) risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20)"}, {"id": "OG001", "title": "Placebo", "description": "Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe consisting of matching placebo to risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "109"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "20.00", "lowerLimit": "16.00", "upperLimit": "25.00"}, {"groupId": "OG001", "value": "37.00", "lowerLimit": "31.00", "upperLimit": "45.00"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "This was analyzed by using a Cox proportional hazards model that included treatment and the stratification factor of OCS use at baseline as fixed effects.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0131", "statisticalMethod": "Cox proportional hazards model", "paramType": "Hazard Ratio (HR)", "paramValue": "1.47", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.20", "ciUpperLimit": "1.79", "estimateComment": "Comparison of Risankizumab to Placebo"}]}, {"type": "SECONDARY", "title": "Annualized Rate of Asthma Worsening During the Planned 24 Week Treatment Period", "description": "Annualized rate of asthma worsening during the planned 24 week treatment period.\n\nAsthma worsening was defined as the occurrence of any one of the following four criteria:\n\na) Decrease from baseline of \u226530% in morning peak expiratory flow (PEF) on at least 2 consecutive days. b) Increase from baseline of \u226550% and an increase of least 4 puffs in daily use of rescue medication for at least 2 consecutive days. c) Increase from baseline of \u22650.75 units in ACQ5. d) Severe asthma exacerbations defined as initiation of systemic corticosteroids (prednisone or equivalent) for 3 or more consecutive days for asthma. Additionally, for subjects on maintenance systemic corticosteroids, at least doubling of the maintenance dose resulting in a total daily dose of \u2265 20 mg for three or more consecutive days was considered a severe asthma exacerbation.\n\nMean is Annualized rate.", "populationDescription": "Full Analysis Set (FAS): All randomized patients who received at least one dose of treatment.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Events per patient year", "timeFrame": "24 weeks", "groups": [{"id": "OG000", "title": "Risankizumab", "description": "Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe with 90 milligram/ milliliter (mg/mL) risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20)"}, {"id": "OG001", "title": "Placebo", "description": "Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe consisting of matching placebo to risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "109"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.8412", "spread": "0.577"}, {"groupId": "OG001", "value": "3.2410", "spread": "0.401"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Annualized rate is obtained from fitting a negative binomial regression including logarithm of the exposure as an offset, treatment, and OCS use at baseline as covariate.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0065", "statisticalMethod": "Negative binomial regression", "paramType": "Rate Ratio", "paramValue": "1.4937", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.2366", "ciUpperLimit": "1.8044", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.220", "estimateComment": "Comparison of Risankizumab to Placebo"}]}, {"type": "SECONDARY", "title": "Time to First Severe Asthma Exacerbation During the Planned 24 Week Treatment Period", "description": "Time to first severe asthma exacerbation during the planned 24 week treatment period. Severe asthma exacerbation was defined as initiation of systemic corticosteroids (prednisone or equivalent) for 3 or more consecutive days for asthma. Additionally, for subjects on maintenance systemic corticosteroids, at least doubling of the maintenance dose resulting in a total daily dose of \u2265 20 mg for three or more consecutive days was considered a severe asthma exacerbation.", "populationDescription": "Full Analysis Set (FAS): All randomized patients who received at least one dose of treatment. NA = not estimable due to an insufficient numbers of patient with an event", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "80% Confidence Interval", "unitOfMeasure": "Days", "timeFrame": "24 weeks", "groups": [{"id": "OG000", "title": "Risankizumab", "description": "Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe with 90 milligram/ milliliter (mg/mL) risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20)"}, {"id": "OG001", "title": "Placebo", "description": "Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe consisting of matching placebo to risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "109"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Not estimable due to an insufficient numbers of patient with an event"}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Not estimable due to an insufficient numbers of patient with an event"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Time to first event is obtained from fitting a Cox proportional-hazards model including treatment, and OCS use at baseline as covariate", "nonInferiorityType": "SUPERIORITY", "pValue": "0.4619", "statisticalMethod": "Cox proportional hazards model", "paramType": "Hazard Ratio (HR)", "paramValue": "1.18", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.88", "ciUpperLimit": "1.57", "estimateComment": "Comparison of Risankizumab to Placebo"}]}, {"type": "SECONDARY", "title": "Annualized Rate of Severe Asthma Exacerbation During the Planned 24-week Treatment Period", "description": "Annualized rate of severe asthma exacerbation during the planned 24-week treatment period.\n\nSevere asthma exacerbation was defined as initiation of systemic corticosteroids (prednisone or equivalent) for 3 or more consecutive days for asthma. Additionally, for subjects on maintenance systemic corticosteroids, at least doubling of the maintenance dose resulting in a total daily dose of \u2265 20 mg for three or more consecutive days was considered a severe asthma exacerbation.\n\nMean is Annualized rate.", "populationDescription": "Full Analysis Set (FAS): All randomized patients who received at least one dose of treatment.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Events per patient year", "timeFrame": "24 weeks", "groups": [{"id": "OG000", "title": "Risankizumab", "description": "Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe with 90 milligram/ milliliter (mg/mL) risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20)"}, {"id": "OG001", "title": "Placebo", "description": "Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe consisting of matching placebo to risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "109"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.5901", "spread": "0.257"}, {"groupId": "OG001", "value": "1.4051", "spread": "0.228"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Annualized rate is obtained from fitting a negative binomial regression including logarithm of the exposure as an offset, treatment, and OCS use at baseline as covariate.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.5550", "statisticalMethod": "Negative binomial regression", "paramType": "Rate Ratio", "paramValue": "1.1317", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.8652", "ciUpperLimit": "1.4803", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.237", "estimateComment": "Comparison of Risankizumab to Placebo"}]}, {"type": "SECONDARY", "title": "Trough Forced Expiratory Volume in 1 Second (FEV1) In-clinic Change From Baseline at Week 24", "description": "Trough forced expiratory volume in 1 second (FEV1) in-clinic change from baseline at week 24.", "populationDescription": "Full Analysis Set (FAS): All randomized patients who received at least one dose of treatment. One patient not included in the analysis due to missing baseline value. Number of patients with either baseline or on-treatment data at the respective week and does not require having both.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter (L)", "timeFrame": "Baseline and 24 weeks", "groups": [{"id": "OG000", "title": "Risankizumab", "description": "Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe with 90 milligram/ milliliter (mg/mL) risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20)"}, {"id": "OG001", "title": "Placebo", "description": "Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe consisting of matching placebo to risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "109"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.052", "spread": "0.036"}, {"groupId": "OG001", "value": "-0.013", "spread": "0.035"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The adjusted mean (SE) are obtained from fitting a mixed effect repeated measures (MMRM) model including treatment, OCS use at baseline, test day, treatment-by-test day interaction, baseline, and baseline-by-test day interaction as covariates patient as a random effect.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.4423", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Unstructured covariance structure for within-patient variation", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.039", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.104", "ciUpperLimit": "0.026", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.051", "estimateComment": "Comparison of Risankizumab to Placebo"}]}, {"type": "SECONDARY", "title": "Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) In-clinic Change From Baseline at Week 24", "description": "Post-bronchodilator forced expiratory volume in 1 second (FEV1) in-clinic change from baseline at week 24.", "populationDescription": "FAS: All randomized patients who received at least one dose of treatment. One patient not included in the analysis due to missing baseline value and one patient not included in the analysis due to missing on-treatment data. Number of patients with either baseline or on-treatment data at the respective week and does not require having both.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter (L)", "timeFrame": "Baseline and 24 weeks", "groups": [{"id": "OG000", "title": "Risankizumab", "description": "Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe with 90 milligram/ milliliter (mg/mL) risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20)"}, {"id": "OG001", "title": "Placebo", "description": "Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe consisting of matching placebo to risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "109"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.097", "spread": "0.032"}, {"groupId": "OG001", "value": "-0.030", "spread": "0.032"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The adjusted mean (SE) are obtained from fitting a mixed effect repeated measures (MMRM) model including treatment, OCS use at baseline, test day, treatment-by-test day interaction, baseline, and baseline-by-test day interaction as covariates patient as a random effect.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.1377", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Unstructured covariance structure for within-patient variation", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.068", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.126", "ciUpperLimit": "-0.009", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.045", "estimateComment": "Comparison of Risankizumab to Placebo"}]}, {"type": "SECONDARY", "title": "Weekly Asthma Control Questionaire Score at Week 24", "description": "The score at week 24 is the average of the responses to the five ACQ5 questions for the week preceding the Week 24 visit. The ACQ5 asks patients to rate the severity of their asthma symptoms and the degree to which asthma affected their sleep and other daily activities. The scale for all five ACQ5 questions range from the best possible answer of 0 (No symptoms, None, Never) to the worst possible answer of 6 (very severe, unable to sleep, totally limited). The ACQ5 score can range from 0.0 (best) to 6.0 (worst).", "populationDescription": "Full Analysis Set (FAS): All randomized patients who received at least one dose of treatment. Ten patients excluded from the analysis due to missing data at week 24.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Unit on Scale", "timeFrame": "24 weeks", "groups": [{"id": "OG000", "title": "Risankizumab", "description": "Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe with 90 milligram/ milliliter (mg/mL) risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20)"}, {"id": "OG001", "title": "Placebo", "description": "Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe consisting of matching placebo to risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "109"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.857", "spread": "0.099"}, {"groupId": "OG001", "value": "1.708", "spread": "0.099"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The adjusted mean (SE) are obtained from fitting an analysis of covariance (ANCOVA) model separately for each week including treatment, OCS use at baseline, and baseline as covariates. The weekly averages of daily measurements are calculated before fitting the model.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.1985", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "0.149", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.000", "ciUpperLimit": "0.297", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.115", "estimateComment": "Comparison of Risankizumab to Placebo"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From the administration of first dose of study medication until 16 weeks after last dose of study medication, up to 40 weeks.", "eventGroups": [{"id": "EG000", "title": "Risankizumab", "description": "Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe with 90 milligram/ milliliter (mg/mL) risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20)", "deathsNumAffected": 0, "deathsNumAtRisk": 105, "seriousNumAffected": 14, "seriousNumAtRisk": 105, "otherNumAffected": 84, "otherNumAtRisk": 105}, {"id": "EG001", "title": "Placebo", "description": "Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe consisting of matching placebo to risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20)", "deathsNumAffected": 0, "deathsNumAtRisk": 109, "seriousNumAffected": 21, "seriousNumAtRisk": 109, "otherNumAffected": 80, "otherNumAtRisk": 109}], "seriousEvents": [{"term": "Sudden hearing loss", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}]}, {"term": "Gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}]}, {"term": "Anaphylactic reaction", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}]}, {"term": "Arthritis bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}]}, {"term": "Chronic sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}]}, {"term": "Epstein-Barr virus infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}]}, {"term": "Localised infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 109}]}, {"term": "Respiratory syncytial virus infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}]}, {"term": "Urosepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}]}, {"term": "Ankle fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}]}, {"term": "Radius fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}]}, {"term": "Electrocardiogram T wave abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}]}, {"term": "Lumbar spinal stenosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}]}, {"term": "Rhabdomyolysis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}]}, {"term": "Rotator cuff syndrome", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}]}, {"term": "Dyskinesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}]}, {"term": "Multiple sclerosis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}]}, {"term": "Hydronephrosis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 109}]}, {"term": "Asthmatic crisis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 109}]}, {"term": "Nasal polyps", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 109}]}], "otherEvents": [{"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 109}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 22, "numAtRisk": 109}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 109}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 109}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 109}]}, {"term": "Blood creatine phosphokinase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 109}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 109}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 109}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 65, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 58, "numAtRisk": 109}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 105}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 109}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection."}, "pointOfContact": {"title": "Global Medical Services", "organization": "AbbVie", "email": "abbvieclinicaltrials@abbvie.com", "phone": "1-800-633-9110"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2017-08-17", "uploadDate": "2019-02-26T09:35", "filename": "Prot_000.pdf", "size": 713211}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2017-10-26", "uploadDate": "2019-02-26T09:35", "filename": "SAP_001.pdf", "size": 204867}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Hungary", "Ireland", "Italy"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M10184", "name": "Immunoglobulins", "relevance": "LOW"}, {"id": "M4225", "name": "Antibodies", "relevance": "LOW"}, {"id": "M10122", "name": "Immunoglobulin G", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}